1. Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

2. Randomized Trial of Ferric Citrate in Advanced CKD

3. Multiple Mechanisms Related to Mineral Metabolism and Anemia Contribute to CV Events in CKD

4. Elevated Serum Potassium Is Associated With an Increased Risk for Dialysis

5. Ferric Citrate in Advanced CKD Rationale for Study

6. Ferric Citrate in Advanced CKD Study Schema

7. Patient Disposition

8. Modified Intent to Treat Hemoglobin, TSAT, Ferritin

9. Modified Intent to Treat Phosphate

10. Modified Intent to Treat: PTH, FGF23, and 1,25-OH Vitamin D

11. Time to Dialysis, Death, or Transplant

12. Conclusions of the Study

13. New Methods of Anemia Management in CKD

14. Evolution of CKD Anemia Treatment

15. HIF-PHIs in Clinical Development for the Treatment of Anemia

16. HIF-PHI

17. Other Oral Iron Formulations for Correcting Anemia

18. Safety of Low vs High Dose IV Iron

19. PIVOTAL Trial Proactive IV Iron Therapy in Hemodialysis Patients

20. Clinical Implications of Recent Data in Managing Anemia in CKD

21. Clinical Implications of Ferric Citrate Study

22. Survival According to Phosphate Levels Relative to KDOQI Guidelines in Patients With Non-Dialysis Dependent CKD

23. Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

24. HIF Stabilizers (HIF-PHIs)

25. Iron Management

26. Abbreviations